N-(2-Benzoylphenyl)- l -tyrosine PPARγ Agonists. 2. Structure−Activity Relationship and Optimization of the Phenyl Alkyl Ether Moiety
Jon L. Collins, Steven G. Blanchard, G. Evan Boswell et al. · Journal of Medicinal Chemistry · 1998
We previously reported the identification of (2S)-((2-benzoylphenyl)amino)-3-¿4-[2-(5-methyl-2-phenyloxazol-4-y l)e thoxy]phenyl¿propanoic acid (2) (PPARgamma pKi = 8.94, PPARgamma pEC50 = 9.47) as a potent and selective PPARgamma agonist. We now report the expanded structure-activity relationship around the phenyl alkyl ether moiety by pursuing both a classical medicinal chemistry approach and a solid-phase chemistry approach for analogue synthesis. The solution-phase strategy focused on evaluating the effects of oxazole and phenyl ring replacements of the 2-(5-methyl-2-phenyloxazol-4-yl)ethyl side chain of 2 with several replacements providing potent and selective PPARgamma agonists with improved aqueous solubility. Specifically, replacement of the phenyl ring of the phenyloxazole moiety with a 4-pyridyl group to give 2(S)-((2-benzoylphenyl)amino)-3-¿4-[2-(5-methyl-2-pyridin-4-yloxazol+ ++- 4-yl)ethoxy]phenyl¿propionic acid (16) (PPARgamma pKi = 8.85, PPARgamma pEC50 = 8.74) or a 4-methylpiperazine to give 2(S)-((2-benzoylphenyl)amino)-3-(4-¿2-[5-methyl-2-(4-methylpiperazin+ ++- 1-yl)thiazol-4-yl]ethoxy¿phenyl)propionic acid (24) (PPARgamma pKi = 8.66, PPARgamma pEC50 = 8.89) provided two potent and selective PPARgamma agonists with increased solubility in pH 7.4 phosphate buffer and simulated gastric fluid as compared to 2. The second strategy took advantage of the speed and ease of parallel solid-phase analogue synthesis to generate a more diverse set of phenyl alkyl ethers which led to the identification of a number of novel, high-affinity PPARgamma ligands (PPARgamma pKi's 6.98-8.03). The combined structure-activity data derived from the two strategies provide valuable insight on the requirements for PPARgamma binding, functional activity, selectivity, and aqueous solubility.
Cited by 86 works. doi:10.1021/jm980413z
Authors
- Jon L. Collins
- Steven G. Blanchard
- G. Evan Boswell
- Paul S. Charifson
- Jeff E. Cobb
- Brad R. Henke
- Emily A. Hull-Ryde
- Wieslaw M. Kazmierski
- Debra H. Lake
- Lisa M. Leesnitzer
- James M. Lenhard
- Lisa A. Orband‐Miller
- Yolanda Gray‐Nunez
- Derek J. Parks
- Kelli D. Plunket
- Wei‐Qin Tong
References
- The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
- U.K. Prospective Diabetes Study 16: Overview of 6 Years' Therapy of Type II Diabetes: A Progressive Disease
- PPAR-gamma: adipogenic regulator and thiazolidinedione receptor.
- Thiazolidinediones in the Treatment of Insulin Resistance and Type II Diabetes
- Minimax and maximin distance designs
- Nuclear receptor coactivators
- Design principles for orally bioavailable drugs
- Metabolic Effects of Troglitazone Monotherapy in Type 2 Diabetes Mellitus
- THIAZOLIDINEDIONES
- Studies on antidiabetic agents. 11. Novel thiazolidinedione derivatives as potent hypoglycemic and hypolipidemic agents